No Data
No Data
12 Health Care Stocks Moving In Wednesday's After-Market Session
Candel Therapeutics Announces Oral Presentation of CAN-2409 Data at 2025 ASCO Annual Meeting
Express News | Candel Therapeutics Announces Oral Presentation of Positive Phase 3 Can-2409 Results in Localized Prostate Cancer at Asco 2025
Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
H.C. Wainwright Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $19
Express News | HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $19 Price Target